Clip inhibitors and methods of modulating immune function
OwnerMartha Karen Newell, Evan Newell +2inventors
InventorsMartha Karen Newell, Evan Newell, Haig Keledjian, Michael Agadjanyan
Life of this patent
Estimating the term…
Abstract
The invention relates to methods for modulating the immune function through targeting of CLIP molecules. The result is wide range of new therapeutic regimens for treating, inhibiting the development of, or otherwise dealing with, a multitude of illnesses and conditions, including autoimmune disease, allergic disease transplant and cell graft rejection, cancer, bacterial infection, HIV infection, and AIDS.
Claims75
A composition comprising
- an isolated MHC class II CLIP inhibitor comprising a peptide of SEQ ID NO 49, 58, 59, 61, 62, 66, 67, 68, 69, 76, 77, 78, 81, 82, 86, 89, 90, 92, 104, 109, 110, 112, 117, 128, 129, 133, 136, 140, 141, 144, 146, 148, 149, 150, 154, 156, 157, 161, 162, 164, 168, 171, 172, 175, 177, 179, 186, 187, 188, 190, 191, 192, 196, 197, 201, 204, 205, 210, 217, 218, 220, 221, 222, 226, 227, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, or a variant thereof and a carrier.
-6. (canceled)
(canceled)
A method of treatment for HIV infection comprising administering to a human infected with HIV or at risk of HIV infection a composition comprising a CLIP inhibitor and a pharmaceutically acceptable carrier.
-14. (canceled)
-29. (canceled)
A method for treating a viral infection comprising administering to a subject infected with a virus or at risk of a viral infection a composition comprising a CLIP inhibitor and a pharmaceutically acceptable carrier.
-42. (canceled)
A method for treating a cancer comprising administering to a subject having a cancer a composition comprising a CLIP inhibitor and a pharmaceutically acceptable carrier.
-48. (canceled)
A method for treating an autoimmune disease comprising administering to a subject having autoimmune disease a composition comprising a CLIP inhibitor and a pharmaceutically acceptable carrier.
-55. (canceled)
A method for treating an allergic disease comprising administering to a subject having allergic disease a composition comprising a CLIP inhibitor and a pharmaceutically acceptable carrier.
-58. (canceled)
A peptide having a peptide sequence corresponding to any one of SEQ ID NOs. 49, 58, 59, 61, 62, 66, 67, 68, 69, 76, 77, 78, 81, 82, 86, 89, 90, 92, 104, 109, 110, 112, 117, 128, 129, 133, 136, 140, 141, 144, 146, 148, 149, 150, 154, 156, 157, 161, 162, 164, 168, 171, 172, 175, 177, 179, 186, 187, 188, 190, 191, 192, 196, 197, 201, 204, 205, 210, 217, 218, 220, 221, 222, 226, 227, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, and 324.
A method for identifying a subject sensitive to treatment with a CLIP inhibitor, comprising, determining an MHC class I or II allele of the subject and determining a predicted binding value of the peptide for the MHC class I or II allele of the subject, wherein a predicted binding value greater than the predicted binding value of CLIP for MHC class I or II allele is indicative of whether a CLIP inhibitor is effective for displacing CLIP from the MHC class I or II allele of the subject and is a CLIP inhibitor for the subject.
A method of treating a subject with a CLIP inhibitor, comprising, determining an MHC class I or II allele of a subject and administering to the subject a CLIP inhibitor in an effective amount to displace CLIP from a surface of a cell.
-72. (canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
-108. (canceled)
A method of treatment for Lyme disease comprising administering to a human suspected of having Lyme disease a composition comprising a peptide comprising a sequence as set forth in SEQ ID NO 304 and a pharmaceutically acceptable carrier.
-117. (canceled)
A method of treatment for cancer comprising administering to a human suspected of having cancer a Toll Ligand Receptor (TLR) agonist, wherein the TLR is TLR2, TLR 7/8, TLR4, or TLR 9, and a CLP inhibitor in an effective amount to displace CLIP from a surface of a cell.
-120. (canceled)
Dependencies are inferred from the claim text.